Gachon University Gil Medical Center
gilhospital.comTotal trials
90
Active
2
Phase 3
2
Total enrollment
12,251
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Combination therapy | — | — | — | — | — | 1 | |
| Monotherapy | — | — | — | — | — | 1 |
Next readouts
- 2027-09-30
Top conditions
- Hypercholesterolemia7
- Allergic Rhinitis5
- Hypertriglyceridemia4
- Cerebral Ischemia3
- Hypertension3
- Stomach Neoplasm3
- Hypoxia2
- Radius Fractures2
Frequently asked questions about Gachon University Gil Medical Center
- How many clinical trials does Gachon University Gil Medical Center have on ClinicalTrials.gov?
- Gachon University Gil Medical Center is listed as the lead sponsor on 90 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gachon University Gil Medical Center's trials are in Phase 3?
- 2 of Gachon University Gil Medical Center's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Gachon University Gil Medical Center focus on?
- Gachon University Gil Medical Center's most-studied conditions on ClinicalTrials.gov are Hypercholesterolemia, Allergic Rhinitis, Hypertriglyceridemia, Cerebral Ischemia, Hypertension.
- When are Gachon University Gil Medical Center's next clinical trial readouts?
- Gachon University Gil Medical Center has 1 upcoming primary-completion readout tracked here; the soonest is “Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)”, expected around 2027-09-30.